Improvement of insulin sensitivity associated with the prolonged use of Acipimox in ++a morbid obese patient Mejoría de la insulinosensibilidad asociada al uso prolongado de Acipimox en un obeso mórbido.
Author
dc.contributor.author
Zura,
Author
dc.contributor.author
Contreras Contreras, Marlene Daniella
Author
dc.contributor.author
Aguirre,
Author
dc.contributor.author
Araya Araya, Fernando
Admission date
dc.date.accessioned
2019-01-29T15:50:04Z
Available date
dc.date.available
2019-01-29T15:50:04Z
Publication date
dc.date.issued
1994
Cita de ítem
dc.identifier.citation
Revista medica de Chile, Volumen 122, Issue 11, 2018, Pages 1298-1302
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/162540
Abstract
dc.description.abstract
Insulin sensitivity was estimated in a morbidity obese, insulin-resistant, glucose-intolerant patient before and after 4 weeks of treatment with Acipimox (250 mg t.i.d), an orally-administered, long-acting antilypolitic drug. The ensuing fall in circulating levels of fasting free fatty acids was associated with a clear amelioration of insulin resistance, as assessed by a minimal model analysis of a frequently sampled intravenous glucose tolerance test as well as by an oral glucose tolerance test. Similarly, this treatment brought about a reappearance of GH response to oral stimulation with clonidine. The evidence showing Acipimox-induced amelioration of insulin resistance in this patient without diet, exercise or weight loss should encourage exploring the potential utility of this drug in this type of patients.
Improvement of insulin sensitivity associated with the prolonged use of Acipimox in ++a morbid obese patient Mejoría de la insulinosensibilidad asociada al uso prolongado de Acipimox en un obeso mórbido.